Apatinib to combat EGFR-TKI resistance in an advanced non-small cell lung cancer patient with unknown EGFR status: a case report

Lung adenocarcinoma is the most common pathological pattern of lung cancer. During the past decades, a number of targeted agents have been explored to treat advanced lung adenocarcinoma. In the present clinical practice, antagonists of the epidermal growth factor receptor (EGFR) and vascular endothe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Onco Targets Ther
Hlavní autoři: Peng, Yanmei, Cui, Huijuan, Liu, Zhe, Liu, Daiwei, Liu, Fan, Song, Yazhong, Duan, Hua, Qiu, Yuqin, Li, Qiang
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2017
Témata:
Case Report
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5414636/
https://ncbi.nlm.nih.gov/pubmed/28490886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S130990
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky